The changing treatment landscape for MDR/XDR-TB - Can current clinical trials revolutionise and inform a brave new world?

Affiliations

¹ Centre for Clinical Microbiology, Division of Infection and Immunity, University College London, Royal Free Hospital, London, UK. Electronic address: i.honeyborne@ucl.ac.uk.
² University College London (UCL) Respiratory, Division of Medicine, UCL, London, UK; Royal Free Hospital London National Health Service Foundation Trust, London, UK. Electronic address: marclipman@nhs.net.
³ Centre for Clinical Microbiology, Division of Infection and Immunity, University College London, Royal Free Hospital, London, UK; UCL Hospitals and National Institute of Health Research Biomedical Research Centre at UCL Hospitals NHS Foundation Trust, London, UK. Electronic address: a.zumla@ucl.ac.uk.
⁴ Centre for Clinical Microbiology, Division of Infection and Immunity, University College London, Royal Free Hospital, London, UK. Electronic address: t.mchugh@ucl.ac.uk.

Free article

Isobella Honeyborne et al. Int J Infect Dis. 2019 Mar.

Free article

. 2019 Mar:80S:S23-S28.

doi: 10.1016/j.ijid.2019.02.006. Epub 2019 Feb 15.

¹ Centre for Clinical Microbiology, Division of Infection and Immunity, University College London, Royal Free Hospital, London, UK. Electronic address: i.honeyborne@ucl.ac.uk.
² University College London (UCL) Respiratory, Division of Medicine, UCL, London, UK; Royal Free Hospital London National Health Service Foundation Trust, London, UK. Electronic address: marclipman@nhs.net.
³ Centre for Clinical Microbiology, Division of Infection and Immunity, University College London, Royal Free Hospital, London, UK; UCL Hospitals and National Institute of Health Research Biomedical Research Centre at UCL Hospitals NHS Foundation Trust, London, UK. Electronic address: a.zumla@ucl.ac.uk.
⁴ Centre for Clinical Microbiology, Division of Infection and Immunity, University College London, Royal Free Hospital, London, UK. Electronic address: t.mchugh@ucl.ac.uk.